NASDAQ : FTH
Faeth Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 18.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 484.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 482.96M |
| Enterprise Value | 297.11M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 25.84M |
| Shares Outstanding | 25.84M |
| Shares Change (YoY) | +88.34% |
| Shares Change (QoQ) | +335.75% |
| Owned by Insiders (%) | 4.27% |
| Owned by Institutions (%) | 41.96% |
| Float | 18.51M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.79 |
| P/TBV Ratio | 2.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 19.69 |
| Quick Ratio | 19.46 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,148.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -195.26% |
| Return on Assets (ROA) | -20.79% |
| Return on Invested Capital (ROIC) | -22.59% |
| Return on Capital Employed (ROCE) | -20.46% |
| Weighted Average Cost of Capital (WACC) | 2.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$6.74M |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.29 |
| 52-Week Price Change | +99.36% |
| 50-Day Moving Average | 28.80 |
| 200-Day Moving Average | 25.14 |
| Relative Strength Index (RSI) | 34.79 |
| Average Volume (20 Days) | 386,575 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.32M |
| Short Previous Month | 2.07M |
| Short % of Shares Out | 8.98% |
| Short % of Float | 12.54% |
| Short Ratio (days to cover) | 5.41 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -36.76M |
| Pretax Income | -195.53M |
| Net Income | -195.53M |
| EBITDA | -36.64M |
| EBIT | -36.76M |
| Earnings Per Share (EPS) | -$82.46 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 186.44M |
| Total Debt | 592,000 |
| Net Cash | 185.85M |
| Net Cash Per Share | $7.19 |
| Equity (Book Value) | 172.96M |
| Book Value Per Share | 6.70 |
| Working Capital | 179.08M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -33.86M |
| Capital Expenditures | -6,000 |
| Depreciation & Amortization | 123,000 |
| Net Borrowing | -345,000 |
| Free Cash Flow | -33.86M |
| FCF Per Share | -$1.31 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -88.34% |
| Shareholder Yield | -88.34% |
| Earnings Yield | -441.19% |
| FCF Yield | -7.01% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $55.38 |
| Price Target Difference | 196.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |